Announcements Trials
Browse Landscape

Status

Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Genitourinary 2Other neoplasm 1Myeloid 1Lymphoid 1Gastrointestinal 1CNS 1

Conditions

Brain Neoplasms 2313Glioblastoma 2016Glioma 1402Central Nervous System Neoplasms 692Astrocytoma 668Neuroblastoma 647Gliosarcoma 480Oligodendroglioma 405Neoplasms 405Breast Neoplasms 327Medulloblastoma 307Carcinoma, Non-Small-Cell Lung 256Meningioma 229Recurrence 224Sarcoma 215Melanoma 207Neoplasm Metastasis 202Ependymoma 200Lung Neoplasms 199Neurofibromatosis 1 169Lymphoma 162Meningeal Carcinomatosis 138Osteosarcoma 135Ovarian Neoplasms 132Wilms Tumor 123Precursor Cell Lymphoblastic Leukemia-Lymphoma 123Head and Neck Neoplasms 117Lymphoma, Non-Hodgkin 116Diffuse Intrinsic Pontine Glioma 113Rhabdomyosarcoma 107

Interventions

vorasidenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Disease Attributes × CNS × Clear all
NCT05592743 2024-11-05

Vorasidenib Expanded Access Program

Servier

Approved for marketing
CNS

Astrocytoma, Glioma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Glandular and Epithelial, Neoplasms, Nerve Tissue, Oligodendroglioma, Pathologic Processes, Recurrence, Neuroectodermal Tumors, Neoplasms, Neuroepithelial, Disease Attributes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡